全文获取类型
收费全文 | 635篇 |
免费 | 37篇 |
国内免费 | 5篇 |
专业分类
儿科学 | 36篇 |
妇产科学 | 20篇 |
基础医学 | 85篇 |
口腔科学 | 2篇 |
临床医学 | 73篇 |
内科学 | 164篇 |
皮肤病学 | 53篇 |
神经病学 | 39篇 |
特种医学 | 25篇 |
外科学 | 43篇 |
综合类 | 13篇 |
预防医学 | 64篇 |
眼科学 | 7篇 |
药学 | 40篇 |
肿瘤学 | 13篇 |
出版年
2021年 | 8篇 |
2020年 | 5篇 |
2019年 | 6篇 |
2018年 | 10篇 |
2017年 | 9篇 |
2016年 | 8篇 |
2015年 | 9篇 |
2014年 | 13篇 |
2013年 | 24篇 |
2012年 | 16篇 |
2011年 | 14篇 |
2010年 | 17篇 |
2009年 | 10篇 |
2008年 | 24篇 |
2007年 | 22篇 |
2006年 | 29篇 |
2005年 | 23篇 |
2004年 | 25篇 |
2003年 | 18篇 |
2002年 | 32篇 |
2001年 | 21篇 |
2000年 | 19篇 |
1999年 | 19篇 |
1998年 | 16篇 |
1997年 | 4篇 |
1996年 | 13篇 |
1995年 | 8篇 |
1994年 | 7篇 |
1993年 | 18篇 |
1992年 | 10篇 |
1991年 | 8篇 |
1990年 | 16篇 |
1989年 | 20篇 |
1988年 | 19篇 |
1987年 | 20篇 |
1986年 | 16篇 |
1985年 | 18篇 |
1984年 | 9篇 |
1983年 | 19篇 |
1982年 | 12篇 |
1981年 | 11篇 |
1980年 | 10篇 |
1979年 | 8篇 |
1978年 | 7篇 |
1977年 | 4篇 |
1975年 | 2篇 |
1974年 | 4篇 |
1961年 | 2篇 |
1956年 | 3篇 |
1838年 | 2篇 |
排序方式: 共有677条查询结果,搜索用时 15 毫秒
41.
42.
Sera containing insulin antibodies from 20 insulin-treated diabetic patients, sera containing insulin autoantibodies from 20 insulin-naive non-diabetic patients, and from 10 normal controls, were tested at 1:20 dilution in three different radioimmunoassays (RIA) and an enzyme linked immunosorbent assay (ELISA), using a highly purified human insulin ligand. The RIA using insulin radiolabelled at multiple sites detected insulin antibodies in 17/20 and insulin autoantibodies in 13/20 sera. The same RIA using A-14-monoiodinated insulin was sensitive to antibodies and autoantibodies in all the sera. The same RIA using sera after insulin extraction detected only 13/20 diabetic sera and 9/20 autoimmune sera as positive, owing to a substantial rise in non-specific binding of the control sera. ELISA was sensitive to insulin antibodies and autoantibodies in every case. When binding curves for ELISA and the most sensitive RIA were compared using serial dilutions of four insulin antibody containing sera and four insulin autoantibody containing sera, antibody titres varied from 1.1 to 3.8 times higher in ELISA, and autoantibody titres from 10.6 to 28.6 times higher in ELISA. These studies indicate that ELISA is more sensitive than RIA to insulin antibodies, and in particular to insulin autoantibodies. 相似文献
43.
44.
The autoradiographic distribution of [3H]arginine vasopressin, [3H]spiperone, [3H]GABA, [3H]dihydroalprenolol and the peripheral-type benzodiazepine ligand [3H]Ro5-4864 were examined in the rat pituitary before and after pituitary stalk transection. Stalk transection produced dramatic changes in the cellular architecture of the pars nervosa. Glial fibrillary acidic protein, an astrocyte marker reported in pituicytes, increased after stalk transection, whereas neurofilament, a marker for neuronal innervation, was lost. These structural changes demonstrated a successful stalk transection, permitting interpretation of changes in the densities of several [3H]-ligands over the three lobes. [3H]Ro5-4864 binding was markedly increased, suggesting that this site was located on the pituicytes. Conversely [3H]spiperone and [3H]arginine vasopressin binding density over the pars nervosa decreased. In the mutant diabetes insipidus rat (Brattleboro), which lacks pituitary vasopressin, [3H]arginine vasopressin binding was undetectable in the pars nervosa. [3H]dihydroalprenolol and [3H]GABA binding sites were unchanged by the lesion. These results are discussed in terms of the occurrence of functional acceptors on pituicytes and their possible role in neurohydrophyseal secretions. 相似文献
45.
Astrocyte heterogeneity. 总被引:8,自引:0,他引:8
46.
目的:目前电磁辐射对生物体行为学方面的研究还很薄弱,设立不同磁场的强度和不同照射的周期,观察中频领域磁场照射对小鼠的自主活动和学习记忆的影响。方法:实验于2007-05-10/06-15在清华大学医学院和中国医学科学院药用植物研究所完成。①实验材料:磁场发生装置:中频交变磁场发生装置由清华大学工程物理系医学物理与工程研究所自主研发,可产生频率为40kHz,场强为28.8A/m,28.8kA/m的中频交变磁场。自主活动测试箱:中国医学科学院药用植物研究所提供,为一可封闭的金属箱,内置摄像头。4只黑色塑料测试桶分别置于箱子四角。水迷宫测试箱:中国医学科学院药用植物研究所提供。②实验动物及方法:将80只小鼠随机分为不同场强照射组和对照组。强磁场照射1组:11.6kA/m/40kHz,1h/d,连续照射7d。强磁场照射2组:11.6kA/m/40kHz,2h/d,连续照射7d。强磁场照射3组:11.6kA/m/40kHz,2h/d连续照射15d。弱磁场照射组:28.8kA/m/40kHz,2h/d,连续照射7d。对照组除了未放入磁场照射,其他条件与照射组一致。实验过程中对动物处置符合动物伦理学要求。③实验评估:观察其一般活动的改变,并采用自主活动测试箱和水迷宫测试箱进行测试,观察各组小鼠的自主活动和学习记忆的改变。结果:①一般行为观察:与对照组小鼠对比,经过中频交变磁场照射过的各组小鼠活跃度减低,毛色较差。强磁场照射3组(145G,2h/d,连续15d)于第11天和13天分别死亡1只。②自主活动检测结果:强磁场照射2,3组小鼠的运动路程、运动速度、运动时间明显低于对照组(P<0.05)。③水迷宫测试结果:在学习记忆检测阶段撤掉平台,发现各组动物2min内穿越平台原来所在象限的次数没有明显差别(P>0.05)。结论:中频交变磁场照射会给小鼠的自发活动造成一定影响,对学习记忆没有影响。 相似文献
47.
48.
49.
50.
Gulick RM Su Z Flexner C Hughes MD Skolnik PR Wilkin TJ Gross R Krambrink A Coakley E Greaves WL Zolopa A Reichman R Godfrey C Hirsch M Kuritzkes DR;AIDS Clinical Trials Group Team 《The Journal of infectious diseases》2007,196(2):304-312
BACKGROUND: Vicriviroc, an investigational CCR5 inhibitor, demonstrated short-term antiretroviral activity in a phase 1 study. METHODS: The present study was a double-blind, randomized phase 2 study of vicriviroc in treatment-experienced, human immunodeficiency virus (HIV)-infected subjects experiencing virologic failure while receiving a ritonavir-containing regimen with an HIV-1 RNA level >or=5000 copies/mL and CCR5-using virus. Vicriviroc at 5, 10, or 15 mg or placebo was added to the failing regimen for 14 days, after which the antiretroviral regimen was optimized. The primary end point was the change in plasma HIV-1 RNA levels at day 14; secondary end points included safety/tolerability and HIV-1 RNA changes at week 24. RESULTS: One hundred eighteen subjects were randomized with a median HIV-1 RNA level of 36,380 (4.56 log(10)) copies/mL and a median CD4 cell count of 146 cells/mm(3). At 14 days and 24 weeks, mean changes in HIV-1 RNA level (log(10) copies/mL) were greater in the vicriviroc groups (-0.87 and -1.51 [5 mg], -1.15 and -1.86 [10 mg], and -0.92 and -1.68 [15 mg]) than in the placebo group (+0.06 and -0.29) (P<.01). Grade 3/4 adverse events were similar across groups. Malignancies occurred in 6 subjects randomized to vicriviroc and in 2 to placebo. CONCLUSIONS: In HIV-1-infected, treatment-experienced patients, vicriviroc demonstrated potent virologic suppression through 24 weeks. The relationship of vicriviroc to malignancy is uncertain. Further development of vicriviroc in treatment-experienced patients is warranted. 相似文献